European Journal of Medicinal Chemistry (2019)
Update date:2022-08-15
Topics:
Du, Qianming
Feng, Xi
Wang, Yinuo
Xu, Xi
Zhang, Yan
Qu, Xinliang
Li, Zhiyu
Bian, Jinlei
Targeting indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as an attractive approach for the development of cancer immunotherapy. In this study, a series of phosphonamidate ester containing compounds were designed, synthesized and evaluated for their inhibitory activities against IDO1. Among them, compounds 16, 17, and 26 with good IDO1 inhibitory (HeLa IDO1 IC50 = 10–21 nM, hIDO1 IC50 = 78–121 nM) activities were selected for further investigation and showed good physicochemical properties. Furthermore, based on comparable PK profile and excellent IDO2/TDO inhibitory potency, representative compound 16 was selected for further bio-evaluation and characterized with good efficacy in suppressing lung metastasis (77% inhibition rate) of Lewis cells in vivo. Thus, compound 16 could be a potential and efficacious agent for further evaluation.
View MoreJinzhou Jiutai Pharmaceutical Co.,Ltd
Contact:+86-0416-5179890
Address:No.41, Taianli, Taihe District, Jinzhou, Liaoning
YingYing Pharmaceutical Co.,Ltd
Contact:86-18854126208
Address:55#, yingxiongshan road
Yingkou Sanzheng New Technology Chemical Industry Co., Ltd.
Contact:+86-417-2927806
Address:yingkou
Antaeus Bio-technology Co., LTD
Contact:021-31252569
Address:shanghai pudong
SHANXI JINJIN CHEMICAL INDUSTRIAL CO.,LTD
website:http://www.jinjingroup.com
Contact:4009982989
Address:Economic And Technological Development Zone,Hejin?City,Shanxi Province?,China
Doi:10.1016/S0022-1139(00)80470-4
(1993)Doi:10.1021/ja00405a088
(1981)Doi:10.1021/om060716o
(2006)Doi:10.1016/j.tetlet.2019.151203
(2019)Doi:10.1021/ol0623825
(2006)Doi:10.1002/anie.200602917
(2006)